Frederick Locke

Hematology | Oncology

12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 269 publications

Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

Journal: Blood immunology & cellular therapy

Published: July 08, 2026

Correction: Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Correction: Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Journal: Journal of cancer education : the official journal of the American Association for Cancer Education

Published: June 19, 2026

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Journal: Transplantation and cellular therapy

Published: April 15, 2026

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Journal: Transplantation and cellular therapy

Published: April 15, 2026

A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.

A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.

Journal: medRxiv : the preprint server for health sciences

Published: April 10, 2026

Pre-infusion plasma proteomics identifies an endothelial-immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma.

Pre-infusion plasma proteomics identifies an endothelial-immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma.

Journal: medRxiv : the preprint server for health sciences

Published: April 10, 2026

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Journal: Blood advances

Published: April 08, 2026

Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT).

Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT).

Journal: Bone marrow transplantation

Published: January 13, 2026

Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells.

Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells.

Journal: Transplantation and cellular therapy

Published: January 05, 2026

Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Journal: Journal of cancer education : the official journal of the American Association for Cancer Education

Published: January 04, 2026

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Journal: Journal of hematology & oncology

Published: December 30, 2025

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Journal: bioRxiv : the preprint server for biology

Published: December 19, 2025

Showing 1-12 of 269

Last Updated: 09/26/2026